Financings for Feb. 18, 2020

Published

February 18, 2020

Financings for Feb. 18, 2020

Omass Therapeutics, of Oxford, U.K., which is harnessing mass spectrometry and other biophysical technologies to drive drug discovery, said it completed an extended series A financing of £27.5 million (US$35.757 million) from existing investors Syncona Ltd. and Oxford Sciences Innovation, bringing the total series A round to £41.5 million…

MORERelated News
Is big pharma falling back in love with small molecules?
New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell...
Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors
When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond...
UK biotech OMass raises £27.5m for GPCR drug discovery
Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund...